NCT04156178: CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies |
|
|
| Unknown status | 1 | 12 | RoW | CD20-CD19 cCAR T cells | iCell Gene Therapeutics, Peking University Shenzhen Hospital, Chengdu Military General Hospital, iCAR Bio Therapeutics Ltd. | B Cell Lymphoma, B Cell Leukemia | 09/20 | 09/20 | | |
